Evidence map›Paper›PMID 41807794›Full record

ArticleArchives of toxicology2026

Prediction of human exposure and first-pass metabolism of the fungicide trifloxystrobin using an in vitro intestinal pancreatin and Caco-2/HT29-MTX model.

Eileen Hallscheidt, Kathrin Bothe, Maria Hahn, Kerstin Hartmann, Mario Thevis, Marc Lamshoeft

Abstract read
In one paragraph

Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eileen HallscheidtCenter for Preventive Doping Research, Institute of Biochemistry, German Sport University Cologne, 50933, Cologne, Germany.ORCID 0009-0002-2605-1247
Kathrin BotheRegulatory Toxicology, Human Safety, Division Crop Science, Bayer AG, 40789, Monheim, Germany.
Maria HahnMetabolism and Kinetics, Environmental Safety, Division Crop Science, Bayer AG, 40789, Monheim, Germany.
Kerstin HartmannRegulatory Toxicology, Human Safety, Division Crop Science, Bayer AG, 40789, Monheim, Germany.
Mario ThevisCenter for Preventive Doping Research, Institute of Biochemistry, German Sport University Cologne, 50933, Cologne, Germany.
Marc LamshoeftMetabolism and Kinetics, Environmental Safety, Division Crop Science, Bayer AG, 40789, Monheim, Germany. marc.lamshoeft@bayer.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conducting toxicological risk assessment of agrochemicals for human health and safety lacks human data and is predominantly based on experimental data obtained from in vivo animal studies. In alignment with the 3R approach (reduce, refine, replace animal testing) and in support of advancing next generation risk assessment of pesticides for human safety, there is a growing demand of implementing new approach methodologies. Therefore, the fungicide trifloxystrobin was investigated concerning human exposure and intestinal first-pass metabolism for the first time using intestinal new approach methodologies. Simulated intestinal fluid containing pancreatin, along with an optimized static in vitro human gut-model (Caco-2/HT29-MTX cell barriers), were established to study the radiolabeled fungicide. A single dose of 10 µM was applied to the in vitro systems, resembling an estimated exposure to humans upon oral uptake from food and feed crops. Trifloxystrobin underwent mainly phase I metabolism to its carboxylic acid metabolite, before entering the systemic circulation consistent with findings from in vivo studies with rodents. The results agree with published in vivo and in vitro data and indicate that the carboxylic acid metabolite is a primary metabolite formed before hepatic phase II conjugation. Moreover, minimal passage through the in vitro gut barriers, facilitated by extensive metabolism indicated low oral bioavailability in humans. The presented in vitro methodologies provide valuable insights into the interplay between human intestinal metabolism and oral bioavailability, exemplified by the active ingredient trifloxystrobin. Moreover, the opportunity of transferring the models to more complex microphysiological technologies such as organ-on-a-chip systems, represents an additional value of these models regarding future studies on oral absorption, metabolism, and organ interactions in vitro.

Indexed as

AcetatesFungicides, IndustrialIminesMethacrylatesPancreatinStrobilurinsCaco-2 CellsHT29 CellsHumansIntestinal MucosaModels, BiologicalRisk AssessmentAcetatesFungicides, IndustrialIminesMethacrylatesPancreatinStrobilurinstrifloxystrobinHuman in vitro gut-modelMetabolismNew approach methodologiesNext generation risk assessmentPesticidesRegulatory toxicology

Identifiers

PMID41807794
PMCPMC13221433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.